Autres langues Kobayashi Pharmaceutical Co., Ltd. Boerse Muenchen

Actions

KOY

JP3301100008

Produits cosmétiques

Temps réel Boerse Muenchen 16:43:03 01/10/2026			Varia. 5j.	Varia. 1 janv.
38,20 ^EUR	+0,53%		+17,50%	+31,47%

25/09	Kobayashi Pharmaceutical indique qu’aucune décision n’a été prise concernant un éventuel retrait de la cote par NSSK et CVC Capital Partners	MT
24/09	Kobayashi serait en discussions en vue d’un rachat de plus de 500 milliards de yens après l’affaire de la levure de riz rouge	CI

Autres langues

25/09	Kobayashi Pharmaceutical Says No Decision Made on Potential Take-Private Deal by NSSK, CVC Capital Partners
24/09	Kobayashi Reportedly in ¥500 Billion Buyout Talks After Red-Yeast Case
06/08	Kobayashi Pharmaceutical : Financial Overview for Second Quarter of Fiscal 2026(Fiscal Year Ending December 31, 2026)
06/08	Kobayashi Pharmaceutical Co., Ltd. Announces Cash Dividend for the Second Quarter End of Fiscal Year Ending December 31, 2026, Payable on September 3, 2026; Provides Cash Dividend Guidance for Fiscal Year Ending December 31, 2026
06/08	Kobayashi Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2026
06/08	Kobayashi Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026
13/05	Oasis Management Company is making shareholder proposal to Kobayashi Pharmaceutical Co, filing shows
08/05	Kobayashi Pharmaceutical : FY2026（January 1, 2026 - December 31, 2026）1Q Financial Statement Summary
08/05	Kobayashi Pharmaceutical : Financial Overview for First Quarter of Fiscal 2026(Fiscal Year Ending December 31, 2026)
30/03	Kobayashi Pharmaceutical Announces the 108th Ordinary General Meeting Results
10/03	Glass Lewis Controversy Alert: Kobayashi Pharmaceutical
06/03	Oasis Management Company Urges Shareholders to Oppose Kobayashi Pharma?s Transition
06/03	Oasis Urges Shareholders to Oppose Kobayashi Pharma’s Transition to a Company with an Audit and Supervisory Committee at AGM (Securities Code: 4967 JT)
03/03	Kobayashi Pharmaceutical Announces Partial Withdrawal of Shareholder Proposal Ahead of 108th Annual General Meeting
10/02	Kobayashi Pharmaceutical Opposes Shareholder Proposals from Oasis Japan Strategic Fund
10/02	Kobayashi Pharmaceutical Opposes Shareholder Proposals from Oasis Japan Strategic Fund
21/01	Oasis Submits Shareholder Proposals to Kobayashi Pharmaceutical
21/01	Oasis urges Kobayashi Pharma shareholders to vote against re-nomination of Akihiro Kobayashi and Yoshiro Katae
21/01	Oasis Submits Shareholder Proposals to Kobayashi Pharmaceutical for 2026 AGM
26/12	Oasis Management raises stake in Kobayashi Pharmaceutical to 13.06% from 10.10%, filing shows
11/11	Kobayashi Pharmaceutical : Financial Overview for Third Quarter of Fiscal 2025(Fiscal Year Ending December 31, 2025)
14/10/25	Court Proceedings Begin in Oasiss Shareholder Derivative Lawsuit Seeking Director Accountability for Kobayashi Pharmaceutical Beni Koji Supplement Tragedy
14/10/25	Court Proceedings Begin in Oasis’s Shareholder Derivative Lawsuit Seeking Director Accountability for Kobayashi Pharmaceutical Beni-Koji Supplement Tragedy
12/06/25	Kobayashi Pharmaceutical Co., Ltd. Require Kazumasa Kobayashi and Akihiro Kobayashi to Resign from Their Roles as Special Advisor and Director in Charge of Compensation, Respectively
12/06/25	Voting Cards Reveal that Over 50% of Shareholders Excluding the Founding Family and Related Parties Voted For Oasis’s EGM Proposals and Against Mr. Akihiro Kobayashi’s Renomination at the AGM